Objective  To explore clinical effect and safety of rivaroxaban in treatment of acute pulmonary thromboembolism at moderate risk with deep vein thrombosis of lower limbs. Methods  The clinical data of 60 patients with acute pulmonary thromboembolism at moderate risk with deep vein thrombosis of lower limbs, collected from January 2010 to March 2017 in Hunan Provincial People’s Hospital, were retrospectively analyzed. According to the different treatment, these patients were randomly divided into a rivaroxaban group and a control group (traditional warfarin anticoagulation), with 30 patients in each group. The clinical effect and safety were compared between two groups on the 10^th day, 20^th day and 30^th day after treatment. Results  Compared with the control group, maximum short axis diameter, ratio of right and left ventricles, systolic pulmonary artery pressure, and main pulmonary artery diameter measured by CTPA and echocardiography in the rivaroxaban group were not significantly different on the 10^th day, 20^th day and 30^th day after treatment. However, the intragroup differences were statistically significant at different timepoint (P<0.05). Levels of N-terminal-pro-brain natriuretic peptide of two groups after treatment were significantly reduced on the 10^th day, 20^th day and 30^th day after treatment, and the values of PO₂ were significantly increased on the 10^th day and 20^th day after treatment (P<0.05), but no significant differences were found in the values of PO₂ on 20^th day and 30^th day after treatment. D-dimer in the two groups was obviously increased on the 10^th day after treatment but significantly declined on the 20^th day and 30^th day after treatment (all P<0.05). These changes were predominant in the rivaroxaban group. Conclusion  Rivaroxaban is effective and safe for acute pulmonary thromboembolism at moderate risk with deep vein thrombosis of lower limbs, and worthy of clinical implementation and application.

Citation： JIANG Gang, ZHANG Weidong, PENG Minlian. Effect of rivaroxaban in patients with acute pulmonary thromboembolism at moderate risk with deep vein thrombosis of lower limbs. Chinese Journal of Respiratory and Critical Care Medicine, 2018, 17(2): 172-177. doi: 10.7507/1671-6205.201704018 Copy